Guest Editors
Assist. Prof. Panagiotis J. Vlachostergios
Email: pjv9003@med.cornell.edu
Affiliation: Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, 10065, USA; Department of Medical Oncology, IASO Thessalias General Hospital, Larissa, 41500, Greece
Homepage:
Research Interests: DNA repair, homologous recombination, genitourinary malignancies, cancer genetics, cancer genomics, precision oncology, immunooncology, biomarker research
Assoc. Prof. Stergios Boussios
Email: stergiosboussios@gmail.com
Affiliation: Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, 45110, Greece; Department of Medical Oncology, University Hospital of Ioannina, Ioannina, 45500, Greece
Homepage:
Research Interests: homologous recombination of DNA, biomarkers, PARP inhibitors
Summary
DNA repair mechanisms are critical for preserving genomic integrity, but are frequently defective in cancer, providing opportunities for therapeutic targeting. Targeting DNA repair pathways (e.g., homologous recombination, base excision repair, and mismatch repair) has advanced as an effective cancer therapeutic approach, with PARP inhibitors providing the prototype for the use in BRCA mutant cancers. Current studies are revealing novel synthetic lethal interactions, resistance mechanisms, and combination regimens that could expand the applicability of DNA repair-targeted therapies. Knowledge of the crosslinking repair pathway, cancer microenvironment, and immune response also raises the prospect of new routes in precision medicine.
Original research articles, reviews, opinions, etc., are welcome for our coming special issue "Targeting DNA Repair in Cancer." This collection will discuss new discoveries in DNA repair. This series will describe the development of therapeutic strategies for DNA repair pathways, mechanisms of resistance to DNA repair inhibitors, new biomarkers for patient stratification, and novel combination strategies. We especially encourage manuscripts that connect fundamental mechanistic work with clinical applications, discuss translational prospects, or propose new avenues in using synthetic lethality. Contributions from academia as well as industry are solicited. Come work with us in the frontiers of precision oncology.
Keywords
DNA repair, cancer therapeutics, synthetic lethality, PARP inhibitors, homologous recombination, genomic instability, tumor microenvironment, resistance mechanisms, precision oncology, DNA damage response (DDR), biomarkers, combination therapy, targeted therapy, BRCA mutations, translational research
Login
Register
Submit a Paper
Propose a Special lssue